Goldman Sachs positive on Natera (NTRA) Medicare coverage for MRD Breast
Tweet Send to a Friend
Goldman Sachs analyst Matthew Sykes reiterated a Buy rating and $80.00 price target on Natera (NASDAQ: NTRA) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
